Myelin — the lipid-rich electrical insulator produced by oligodendrocytes in the CNS — is essential for rapid saltatory conduction and metabolic support of axons. Myelin pathology is a common and early feature across Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Huntington's disease (HD), though the underlying mechanisms differ substantially between diseases[@nave2014][@emery2010].
Oligodendrocytes are uniquely vulnerable due to high metabolic demands, iron-rich environment, and dependence on axonal signals for survival. Each disease presents a distinct pattern: tau pathology in AD affects oligodendrocyte viability; alpha-synuclein in PD disrupts myelin maintenance; TDP-43 pathology in ALS/FTD drives oligodendrocyte-specific transcriptional dysfunction; and mutant huntingtin in HD causes widespread transcriptional repression of myelin genes[@depp2018][@reih2017][@rose2023].
Myelin — the lipid-rich electrical insulator produced by oligodendrocytes in the CNS — is essential for rapid saltatory conduction and metabolic support of axons. Myelin pathology is a common and early feature across Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and Huntington's disease (HD), though the underlying mechanisms differ substantially between diseases[@nave2014][@emery2010].
Oligodendrocytes are uniquely vulnerable due to high metabolic demands, iron-rich environment, and dependence on axonal signals for survival. Each disease presents a distinct pattern: tau pathology in AD affects oligodendrocyte viability; alpha-synuclein in PD disrupts myelin maintenance; TDP-43 pathology in ALS/FTD drives oligodendrocyte-specific transcriptional dysfunction; and mutant huntingtin in HD causes widespread transcriptional repression of myelin genes[@depp2018][@reih2017][@rose2023].
| Feature | Alzheimer's Disease | Parkinson's Disease | ALS | FTD | Huntington's Disease |
|---------|---------------------|---------------------|-----|-----|----------------------|
| Primary Myelin Abnormality | WMH, myelin thinning, fragmentation | Myelin breakdown, oligodendrocyte loss | Primary oligodendrocyte dysfunction, demyelination | Oligodendrocyte loss, myelin gene dysregulation | Widespread demyelination, myelin gene repression |
| Oligodendrocyte Pathology | OPC senescence, reduced differentiation | Alpha-synuclein in oligodendrocytes | TDP-43 in oligodendrocytes, transcriptional loss | GRN/TDP-43 effects on oligodendrocyte survival | mHTT transcriptional repression of myelin genes |
| White Matter Lesions | Extensive WMH on MRI, periventricular | Diffuse white matter changes | Tract-specific demyelination (corticospinal) | Frontotemporal white matter atrophy | Striatal and subcortical white matter loss |
| Myelin Protein Changes | MBP, PLP reduction | MBP reduction, CNPase loss | MBP, PLP, MOG reduction | MBP, PLP, CNPase reduction | PLP, MBP significant reduction |
| Iron Accumulation | Iron in myelin, oxidative stress | Iron in substantia nigra, oligodendrocytes | Iron accumulation in motor cortex | Variable iron accumulation | Iron in striatum, white matter |
| Remyelination Capacity | OPCs present but fail to differentiate | OPCs present, microenvironment impaired | OPCs reduced, microenvironment hostile | OPCs reduced, TDP-43 impairs function | OPCs reduced, metabolic support impaired |
| Key Molecular Mechanism | Aβ toxicity, tau in oligodendrocytes | Alpha-synuclein inclusions | TDP-43 loss of function | TDP-43, progranulin | mHTT transcriptional repression |
| Clinical Correlation | Cognitive decline, gait impairment | Motor symptoms, cognitive decline | Motor neuron dysfunction | Frontotemporal cognitive decline | Chorea, cognitive decline |
WMH = white matter hyperintensities; OPC = oligodendrocyte precursor cell; MBP = myelin basic protein; PLP = proteolipid protein; CNPase = 2',3'-cyclic nucleotide 3'-phosphodiesterase
Oligodendrocytes produce myelin sheaths that wrap axons in a lipid-rich, multi-layered membrane structure. A single oligodendrocyte can myelinate up to 50 axons. Myelin functions include:
Myelin pathology is an early and widespread feature of AD, often preceding detectable amyloid or tau pathology[@petersen2019][@dean2017].
Amyloid-beta effects on oligodendrocytes:
White matter changes in PD include demyelination and oligodendrocyte loss in substantia nigra and broader brain regions[@depp2018][@fischer2018][@zhu2024].
Alpha-synuclein in oligodendrocytes:
Oligodendrocyte pathology is a major feature of ALS, with TDP-43 inclusions and functional impairment observed in multiple studies[@rose2023][@chen2020].
TDP-43 pathology in oligodendrocytes:
White matter atrophy is prominent in FTD, with distinct patterns across subtypes[@chen2022b][@reih2017].
FTD-TDP (most common):
Huntington's disease shows widespread white matter pathology, with demyelination beginning in pre-symptomatic gene carriers[@lin2019][@hughes2020].
Mutant huntingtin effects on oligodendrocytes:
Iron accumulates in the aging brain and is accelerated across all five neurodegenerative diseases[@wang2018]:
Oligodendrocytes are highly metabolically active cells[@rinholm2011]:
Activated microglia and astrocytes create a hostile microenvironment:
| Strategy | Target | Stage | Evidence |
|----------|--------|-------|----------|
| Clemastine (antihistamine) | M1 muscarinic receptor antagonist | Phase II (AD, MS) | Promotes OPC differentiation; mixed results in AD (NCT02098078) |
| GSK-3β inhibitors | GSK-3β | Preclinical | Promote myelination; cognitive benefits in AD models |
| Deferiprone | Iron chelation | Phase II (PD) | Reduced iron, modest motor benefit in PD (NCT0265533) |
| Deferasirox | Iron chelation | Phase I (ALS) | Iron chelation in ALS |
| Nicotinamide riboside (NR) | NAD+ precursor | Phase II (PD, AD) | Supports oligodendrocyte energy metabolism; NCT03462100 (PD) |
| Bexarotene (retinoid X agonist) | RXR signaling | Phase II (AD) | Promoted Aβ clearance and myelin repair; efficacy disputed |
| S1P receptor modulators (fingolimod) | S1P signaling | Approved (MS), FTD trials | Promotes oligodendrocyte survival and OPC differentiation |
| Minocycline | Microglial inhibition | Phase II (ALS) | Microglial modulation; mixed results |
| Biomarker | Source | Disease | Utility |
|-----------|--------|---------|---------|
| Myelin basic protein (MBP) | CSF | AD, PD, ALS | Marker of demyelination; elevated in active myelin breakdown |
| Myelin oligodendrocyte glycoprotein (MOG) | CSF | AD, ALS | Myelin integrity marker |
| Neurofilament light chain (NfL) | CSF, blood | All 5 diseases | Axonal damage marker; correlates with myelin loss |
| N-acetylaspartate (NAA) | MRS | AD, PD, HD | Neuronal/oligodendrocyte integrity marker; reduced in demyelination |
| Choline | MRS, CSF | AD, PD | Membrane turnover marker; elevated in demyelination |
| Diffusion tensor imaging (DTI) | MRI | All 5 diseases | FA reduction = myelin damage |
| Myelin water imaging | MRI | AD, MS | Direct myelin fraction measurement |